Science news

<<  return

 

 

Adding the drug ivabradine (Procoralan, Servier) to standard therapy had no effect, overall, on cardiovascular events in a placebo-controlled trial that randomized >19 000 patients with stable CAD.

2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/24093844

2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/25176136